MedTrace Logo

Anti-PD-1/PD-L1 Antibodies Plus Pegylated Interferon Alfa-2b Treatment in Patients With Advanced-Stage HCC

NCT04943679 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 15

Last updated 2022-03-31

No results posted yet for this study

Summary

This study is being done to analyze the safety, tolerability, and efficacy of treatment using combination of Pegylated Interferon Alfa-2b and anti-PD-1/PD-L1 antibodies for patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

Anti-PD-1/PD-L1

Intravenous injection for up to 2 years

DRUG

PEG-Interferon Alfa

3 µg/kg every week by subcutaneous injection for up to 2 years

Sponsors & Collaborators

  • Shanghai Zhongshan Hospital

    lead OTHER

Principal Investigators

  • Yang Xu, M.D.&Ph.D · Fudan University

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-15
Primary Completion
2024-12-31
Completion
2024-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04943679 on ClinicalTrials.gov